greeksoup/ stock research
Stock research / United States / INDV / Q4 FY2024

Indivior Pharmaceuticals (INDV) Q4 FY2024 earnings: revenue $298 million

Indivior Pharmaceuticals, Inc. (INDV) reported revenue of $298 million for Q4 FY2024, the quarter ended 31 December 2024. Net income was $21 million, and diluted earnings per share $0.13. The figures are the company's own, from the 10-K it filed with the SEC on 3 March 2025.

Revenue$298 million
Net income$21 million
Diluted EPS$0.13
QuarterQ4 FY2024ended 31 December 2024

The quarter, against the one before and a year earlier

LineQ4 FY2024Q3 FY2024A year earlierChange on the year
Revenue298307n/an/a
Cost of revenue48.066.0n/an/a
Gross profit250241n/an/a
Gross margin83.9%78.5%n/a
Research and development31.022.0n/an/a
Selling, general and administrative175142n/an/a
Operating income46.035.0n/an/a
Operating margin15.4%11.4%n/a
Interest expense12.011.0n/an/a
Pre-tax income38.030.0n/an/a
Income tax17.08.0n/an/a
Effective tax rate44.7%26.7%n/a
Net income21.022.0n/an/a
Net margin7.0%7.2%n/a
Diluted EPS$0.13$0.16n/an/a
$ million except per share.
Read moreFourth quarters are the year less the first three quarters. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.

Cash flow and capital returned

LineQ4 FY2024Q3 FY2024A year earlierChange on the year
Operating cash flow-17.02.0n/an/a
Capital expenditure16.07.0n/an/a
Free cash flow-33.0-5.0n/an/a
Free cash flow margin-11.1%-1.6%n/a
Cash from investing8.035.0n/an/a
Cash from financing40.0-51.0n/an/a
Depreciation and amortisation18.04.0n/an/a
Share-based compensation6.06.0n/an/a
Buybacks50.052.0n/an/a
Diluted shares, weighted133m133mn/an/a
Shares outstanding at period end125m125mn/an/a

Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.

Balance sheet at quarter end

LineQ4 FY2024Q3 FY2024A year earlierChange on the year
Shareholders' equity-348-310n/an/a
Debt315n/an/an/a
Operating lease liabilities32.0n/an/an/a
Other liabilities1,320n/an/an/a
Total liabilities and equity1,319n/an/an/a
Fixed assets100n/an/an/a
Goodwill2.0n/an/an/a
Investments28.0n/an/an/a
Cash and equivalents319288n/an/a
Receivables254n/an/an/a
Inventory178n/an/an/a
Other assets438n/an/an/a
Total assets1,319n/an/an/a

Questions

What was Indivior Pharmaceuticals' revenue in Q4 FY2024?

Indivior Pharmaceuticals (INDV) reported revenue of $298 million for Q4 FY2024, the quarter ended 31 December 2024.

How much did Indivior Pharmaceuticals earn in Q4 FY2024?

Net income for Q4 FY2024 was $21 million, and diluted earnings per share $0.13.

When did Indivior Pharmaceuticals report Q4 FY2024 results?

Indivior Pharmaceuticals filed its 10-K for the year that ended with the quarter on 3 March 2025; the fourth quarter is the year less the first three.

Quarterly results, the last 10 quarters

Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024 *Q1 FY2025 †Q2 FY2025Q3 FY2025Q4 FY2025 *Q1 FY2026 †Q2 FY2026
Revenue284299307298266302314357317343
Cost of revenue38.079.066.048.044.052.083.067.040.050.0
Gross profit246220241250221250230293277294
Gross margin87%74%79%84%83%83%73%82%87%86%
R&D28.026.022.031.022.021.033.021.016.012.0
SG&A143152142175133158155189124122
Operating income75.0-11835.046.066.072.043.0n/a137160
Operating margin26%-39%11%15%25%24%14%n/a43%47%
Interest expense9.09.011.012.012.015.012.06.07.02.0
Pre-tax income73.0-12130.038.059.062.037.0n/a115160
Tax rate15%n/a27%45%19%71%-14%n/a23%24%
Net income61.0-97.022.021.047.018.042.0n/a89.0122
Net margin21%-32%7%7%18%6%13%n/a28%36%
Diluted EPS$0.45-$0.72$0.16$0.13$0.38$0.14$0.33n/a$0.69$0.98
Operating cash flow-37.088.02.0-17.075.0158-39.0-221-9.0229
Capital expenditure2.04.07.016.05.017.020.024.020.07.0
Free cash flow-39.084.0-5.0-33.070.0141-59.0-245-29.0222
Buybacks36.035.052.050.011.00.00.00.0125176
Shares outstanding125m125m125m125m125m125m125m125m122m118m
Filing10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q
Each quarter as filed, linked to its filing.
Read more* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A quarter marked † is shown as the company last restated it in a later filing, so it compares with the quarters around it on one basis; rest on a figure for the one first filed. EPS is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

Source

10-K for the period ended 31 December 2024, filed 3 March 2025, accession 0001625297-25-000016: the filing on EDGAR. All of Indivior Pharmaceuticals, Inc.'s filings: EDGAR company page.

The same record on your computer

GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.

Install